BRUKER CORP (BRKR): what the price requires

At today's price, BRUKER CORP (BRKR) is priced for today's economics sustained for ~5.4 years. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high.

Generated: 2026-07-19 · Exported: 2026-07-20 · Source: https://boothcheck.com/report/BRKR

Headline

FieldValue
TickerBRKR
CompanyBRUKER CORP
Current price$58.97/sh
CompositionBSI BioSpin 26% / BSI CALID 35% / BSI NANO 32% / BEST 8%

What The Price Requires (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

FieldValue
Inversion basiswhole-company
Operating margin needed4.7%
Operating margin (mid-cycle)10.4%
Margin compression implied-5.7pp
Trailing margin (depressed year)0.1%
Must persist for5.4y
Multiple paid31x mid-cycle operating income

The operating-margin requirement is derived from the framework's value band at year 12, a separately labeled basis from the headline growth/duration solve.

Solve inputs: computed at a 8.7% cost of capital; growth searched up to the 25% self-funding ceiling; each 1pp moves the implied horizon ~1.9 years.

How unusual the bet is: within-range

ReferenceValue
vs own history+1.04σ
sustained it ~5.4 years at this level35%
implied end-window share0%

Valuation X-Ray

The price is justified by relative-multiple; asset-based/earnings-power/growth-DCF land below the price.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

FamilyMedian price/FVModelsReads
Asset3.85x2expensive
Earnings3.62x1expensive
Relative1.04x3expensive
Growth1.52x2expensive

Families that justify the price: Relative Families that call it expensive: Asset, Earnings, Growth

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 7.9%); the inversion above states its own rate.

Per-Model Detail (n=8)

ModelFamilyFVPrice/FVApplicableMethodology
DCF Perpetual GrowthGrowth$0.00—noFCF base $0.1B, growth 0% (input: historical growth), terminal g 0.5%, WACC 7.9%, 5yr projection
DCF Exit MultipleGrowth$40.571.45xyesExit EV/EBITDA: 36.4x / 38.4x / 40.4x (bear / base = today's held flat / bull), 5yr
Relative ValuationRelative$56.621.04xyesP/S fallback (negative EPS): Sector P/S 2.5x × TTM revenue — excluded from consensus
Simple DDMGrowth——no—
Two-Stage DDMGrowth——no—
Simple Excess ReturnAsset$16.163.65xyesReference only (book value floor): BV/sh $16.16, ROE negative
Two-Stage Excess ReturnAsset$14.544.06xyesReference only (book value with convergence): BV/sh $16.16, ROE converges to ke
Discounted Future Market CapGrowth$37.091.59xyesRev $3.5B, growth 0% (input: historical growth; tapered), Terminal P/S: 2.2x / 2.6x / 3.0x (bear / base = today's held flat / bull, cap 8x)
Peter Lynch Fair ValueRelative$0.00—noNegative/zero EPS — earnings-based value floored at $0
Margin TrajectoryGrowth——no—
Earnings Power ValueEarnings$16.313.62xyesNormalized EBIT (5y avg op income, one-time charges added back) $0.37B × (1−11%) / WACC 7.9% → EPV (no growth)
Residual IncomeAsset——no—
Graham NumberAsset——no—
EV/EBITDA RelativeRelative$11.525.12xyesEBITDA $0.27B × sector EV/EBITDA 12.0x
FCF YieldEarnings$0.015897.00xyesFCF $51.3M / Kₑ 9.3% — zero-growth perpetuity (excluded from median)
SBC-Adj FCF YieldEarnings$0.015897.00xyesSBC-adj FCF $0.03B (FCF $0.05B − SBC $0.02B) capitalized at Kₑ (excluded from median)
Ben Graham FormulaEarnings——no—
ROIC-Justified P/BAsset$0.46128.20xyesBV $16.16 × (ROIC 0.2% / WACC 7.9%) (excluded from median)
P/Sales SectorRelative$56.621.04xyesRevenue $3.46B × sector P/S 2.5x
PEG Fair ValueRelative——no—
Earnings YieldEarnings——no—
Funds From Operations MultipleRelative——no—
Clinical Phase NPVGrowth——no—
MertonAsset——no—
V5 Mechanical———no—

Solvency

FieldValue
Net debt$1.6b
Net debt / NOPAT (after-tax)5.17x
Net debt / operating income (pre-tax)4.58x
Interest coverage5.5x
Share count CAGR (dilution)0.2%
Burning cashno

Leverage and coverage are computed on normalized mid-cycle operating income (mid-cycle margin 10.4%); the trailing year was depressed.

Bullet Takeaways

At about $57, the price works out to roughly 31 times Bruker's through-the-cycle operating income, and that read leans on the company's own mid-cycle margins rather than the depressed trailing quarter. Only the relative-multiple family supports the price; the asset, earnings-power, and growth-DCF families all land well below it.

The first quarter of 2026 showed the squeeze: revenue of $823.4 million, up about 3% from a year earlier, but non-GAAP operating margin down to 10.2% from 12.7%, with restructuring and impairment charges concentrated in the NANO and CALID instrument segments.

The balance sheet carries real leverage for an instruments company, net debt near $1.56 billion at about 4.3 times trailing operating income, with interest coverage around 6 times. The acquisition-led build adds intangibles and integration work to a year where organic growth is guided at just 1% to 2%.

Bull Case

Valuing a scientific-instruments company like Bruker is its own discipline, and the data here breaks the easy read in a useful way. These businesses sell expensive analytical hardware, NMR and magnetic-resonance systems, mass spectrometers, microscopy and X-ray tools, into research labs, then earn for years afterward on service, consumables, and software tied to the installed base. That recurring tail is what makes the trailing margin misleading: the first quarter of 2026 printed a 10.2% non-GAAP operating margin, depressed by volume, mix, foreign exchange, and tariffs, but the through-the-cycle margin the business has shown is closer to 10.4% and the model is built to mean-revert higher as the cost program lands and the demand cycle turns. The price is paying for that normalized earnings power, not the trough.

The portfolio is the second pillar. Bruker reports across four parts: BioSpin (magnetic resonance), CALID (mass spectrometry and chemical analysis), NANO (microscopy and X-ray), and the smaller BEST superconductor unit. The diversification matters because the end-markets do not all move together, and the company keeps pushing the high end. Investor enthusiasm around the ASMS conference came from next-generation mass-spectrometry and proteomics launches, including a new platform aimed at ultra-complex energy mixtures, the kind of product that protects the high-margin franchise where Bruker competes against Waters and Bio-Rad rather than on price. Tofwerk was folded in fully in January 2026, adding mass-spec capability rather than scale for its own sake.

Management's posture supports the patient read. Bruker reaffirmed full-year 2026 guidance of $3.57 to $3.60 billion in revenue and non-GAAP EPS of $2.10 to $2.15, up 15% to 17% despite a roughly 8% foreign-exchange headwind, and explicitly declined to raise the number on a Q1 beat. (sahmcapital) Sell-side support has been improving rather than fading: Bank of America lifted its target to $65 with a Buy, and Barclays moved to $60 at Overweight. (public.com) If the cost program restores the margin and the academic demand cycle normalizes, the relative-multiple read that justifies today's price has room to look conservative.

Bear Case

The erosion to watch is on the demand side of Bruker's moat, not the technology itself. The instruments are excellent, but a large share of the revenue depends on the research and development budgets of academic institutions, governments, and the biopharma industry, and those budgets are exactly what softened. The FY2025 10-K names the dependency directly: demand rests "upon the research and development budgets of the pharmaceutical and biotechnology industries, and in material science research as well as upon the financial condition and funding" of its customers (FY2025 10-K, accession 0001193125-26-082523). Management tied the weak quarter to soft demand from academic institutions and a slowdown in U.S. biopharma, which hit bookings. A franchise that is technically dominant can still see its growth rate compress when the people who buy the boxes stop getting funded, and that is a slow erosion the price does not yet reflect.

The margin tells the same story from the inside. Non-GAAP operating margin fell to 10.2% from 12.7% a year earlier, a 250 basis-point step down driven by volume, mix, foreign exchange, and tariffs, and the company took $17.8 million of restructuring plus $12.9 million of long-lived asset impairments, concentrated in the NANO and CALID segments. (stocktitan) Impairments in two of the four segments are an admission that some of the acquired assets are worth less than carried. With organic growth guided at only 1% to 2% for 2026, the bull case's reliance on margin recovery is doing nearly all the work, and a corporate cost program that has to finish on schedule to deliver it.

Then there is the price against everything except the relative multiple. Strip out the peer-comparison family and the methods land far below the quote: a normalized earnings-power read near $16, an exit-multiple DCF near $39, a discounted-future-market-cap read near $36, against a price of about $57 (June 27, 2026). The single supportive method is a sector P/S multiple, which is the most forgiving and least anchored of the family. Layer on net debt of about $1.56 billion at roughly 4.3 times operating income, a balance sheet heavier than a clean instruments compounder should carry, and the bet narrows to one thing: that mid-cycle margins return on schedule and the academic and biopharma demand cycle turns back up. If either slips, there is little in the asset or earnings base to catch the price.

Valuation

Bruker prices off normalized earnings power, not the trailing quarter, because the cycle has the trailing numbers depressed. On the company's own through-the-cycle margins applied to current revenue, the price of about $57 works out to roughly 31 times mid-cycle operating income, which inverts into an assumption that company-wide operating growth holds near its self-funding ceiling for about five years. That is not an extreme rate. The stretch is in the duration: history suggests only about a third of comparable fast-growers sustained that pace for roughly five years.

The method families disagree sharply, and the disagreement is the signal. The relative-valuation family sits right at the price, with a sector price-to-sales read near $57. Every other family lands lower: the growth-DCF and discounted-future-market-cap reads in the high $30s, the earnings-power value near $16, and the asset-based reads in the mid-teens reflecting a thin book value and currently negative returns on equity. The blended read across the applicable methods lands near $28, roughly half the current price. In plain terms, you are paying a price that only the most generous, multiple-based method supports, on the expectation that depressed margins normalize.

The conclusion is conditional rather than cheap-or-expensive. At today's price the bet is that Bruker's mid-cycle margin of around 10% returns as the cost program completes and the academic and biopharma demand cycle recovers, restoring the earnings the multiple is paying for. If that happens, the relative read holds and the gap to the other families closes from below. If the margin recovery slips or the demand softness persists, there is little in the asset or zero-growth earnings base to support the current level, and net debt at about 4.3 times operating income leaves less room for patience.

Catalysts

The near-term driver is the margin-recovery story playing out against soft demand. First-quarter 2026 revenue was $823.4 million, up about 3% year over year, but non-GAAP EPS fell to $0.31 from $0.47 and non-GAAP operating margin dropped to 10.2% from 12.7%, with $17.8 million of restructuring and $12.9 million of impairments in the NANO and CALID segments. (stocktitan, Motley Fool) Management reaffirmed full-year guidance of $3.57 to $3.60 billion in revenue and non-GAAP EPS of $2.10 to $2.15, and pointedly declined to raise it on the Q1 beat, citing input-cost and macro uncertainty. (sahmcapital)

Product and deal activity is the upside catalyst. New mass-spectrometry and proteomics launches at the ASMS conference, including a platform aimed at ultra-complex energy mixtures, drove investor enthusiasm and a positive trading reaction into June 2026. (financialcontent) On the deal side, Bruker completed the acquisition of the remaining majority stake in Tofwerk AG on January 8, 2026, continuing its tuck-in strategy in mass spectrometry. Analyst sentiment has firmed, with Bank of America raising its target to $65 at Buy and Barclays moving to $60 at Overweight. (public.com)

The things to watch over the next few quarters: whether academic and U.S. biopharma bookings stabilize, whether the corporate cost program lands the margin recovery on schedule into the back half of 2026, and the pace of foreign-exchange and tariff headwinds that took 250 basis points off the operating margin this quarter. The thesis turns on the margin returning before the leverage and the soft demand cycle force a guide-down.

Peer Cohorts (Per Segment, With Filing Citations)

BSI BioSpin (reported)

BSI CALID (reported)

BSI NANO (reported)

BEST (reported)

Methodology Note

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.

View the full interactive BRKR report on boothcheck